AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The news sent U.S.-listed shares of Novo Nordisk 5% lower, while Eli Lilly stock ticked higher. TradingView Investopedia requires writers to use primary sources to support their work. These ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE ... with basically the same two GLP-1 drug stock prospects they began with: Lilly stock, which costs 70 times earnings and ...